H.C. Wainwright Maintains Buy on BioXcel Therapeutics, Raises Price Target to $30

H.C. Wainwright analyst Raghuram Selvaraju maintains BioXcel Therapeutics (NASDAQ:BTAI) with a Buy and raises the price target from $25 to $30.

Benzinga · 01/08/2020 15:44

H.C. Wainwright analyst Raghuram Selvaraju maintains BioXcel Therapeutics (NASDAQ:BTAI) with a Buy and raises the price target from $25 to $30.